Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

第2相 実施中（募集終了） NCT04739800

概要

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and

Progression Free Survival

From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months). · Months

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
• Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Can — National Cancer Institute (NCI)

すべての治験